Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-304: INCMGA00012 plus platinum chemotherapy with or without placebo as first-line treatment for metastatic squamous and nonsquamous non-small cell lung cancer
CTR20200941Phase 3Active
- Sponsor
- Incyte
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of retifanlimab in non-small cell lung cancer (NSCLC), sponsored by Incyte. Started Sep 2020; status: active.
02
Drugs
retifanlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200941.